TY - JOUR
T1 - Extensive colonization with carbapenemase-producing microorganisms in Romanian burn patients
T2 - infectious consequences from the Colectiv fire disaster
AU - Pirii, L.E.
AU - Friedrich, A.W.
AU - Rossen, J.W.A.
AU - Vogels, W.
AU - Beerthuizen, G.I.J.M.
AU - Nieuwenhuis, M.K.
AU - Kooistra-Smid, A.M.D.
AU - Bathoorn, E.
PY - 2017/10/23
Y1 - 2017/10/23
N2 - Health care of severe burn patients is highly specialized and may require international patient transfer. Burn patients have an increased risk of developing infections. Patients that have been hospitalized in countries where carbapenemase-producing microorganisms (CPMO) are endemic may develop infections that are difficult to treat. In addition, there is a risk on outbreaks with CPMOs in burn centers. This study underlines that burn patients may extensively be colonized with CPMOs, and it provides best practice recommendations regarding clinical microbiology and infection control. We evaluated CPMO-carriage and wound colonization in a burn patient initially treated in Romania, and transported to the Netherlands. The sequence types and acquired beta-lactamase genes of highly-resistant microorganisms were derived from next generation sequencing data. Next, we searched literature for reports on CPMOs in burn patients. Five different carbapenemase-producing isolates were cultured: two unrelated OXA-48-producing Klebsiella pneumoniae isolates, OXA-23-producing Acinetobacter baumanii, OXA-48-producing Enterobacter cloacae, and NDM-1-producing Providencia stuartii. Also, multi-drug resistant Pseudomonas aeruginosa isolates were detected. Among the sampling sites, there was high variety in CPMOs. We found 46 reports on CPMOs in burn patients. We listed the epidemiology of CPMOs by country of initial treatment, and summarized recommendations for care of these patients based on these reports and our study.
AB - Health care of severe burn patients is highly specialized and may require international patient transfer. Burn patients have an increased risk of developing infections. Patients that have been hospitalized in countries where carbapenemase-producing microorganisms (CPMO) are endemic may develop infections that are difficult to treat. In addition, there is a risk on outbreaks with CPMOs in burn centers. This study underlines that burn patients may extensively be colonized with CPMOs, and it provides best practice recommendations regarding clinical microbiology and infection control. We evaluated CPMO-carriage and wound colonization in a burn patient initially treated in Romania, and transported to the Netherlands. The sequence types and acquired beta-lactamase genes of highly-resistant microorganisms were derived from next generation sequencing data. Next, we searched literature for reports on CPMOs in burn patients. Five different carbapenemase-producing isolates were cultured: two unrelated OXA-48-producing Klebsiella pneumoniae isolates, OXA-23-producing Acinetobacter baumanii, OXA-48-producing Enterobacter cloacae, and NDM-1-producing Providencia stuartii. Also, multi-drug resistant Pseudomonas aeruginosa isolates were detected. Among the sampling sites, there was high variety in CPMOs. We found 46 reports on CPMOs in burn patients. We listed the epidemiology of CPMOs by country of initial treatment, and summarized recommendations for care of these patients based on these reports and our study.
KW - acinetobacter baumannii/drug effects
KW - anti-bacterial agents/therapeutic use
KW - bacterial proteins/metabolism
KW - burns/microbiology
KW - colistin/therapeutic use
KW - disasters
KW - enterobacter cloacae/drug effects
KW - humans
KW - kanamycin/therapeutic use
KW - klebsiella pneumoniae/drug effects
KW - linezolid/therapeutic use
KW - microbial sensitivity tests
KW - Netherlands
KW - penicillanic acid/analogs & derivatives
KW - piperacillin/therapeutic use
KW - piperacillin, tazobactam drug combination
KW - providencia/drug effects
KW - pseudomonas aeruginosa/drug effects
KW - Romania
KW - silver sulfadiazine/therapeutic use
KW - beta-lactamases/metabolism
KW - antibacteriële middelen/therapeutisch gebruik
KW - bacteriële proteïnen/stofwisseling
KW - brandwonden/microbiologie
KW - colistine/therapeutisch gebruik
KW - calamiteiten
KW - mensen
KW - kanamycine/therapeutisch gebruik
KW - linezolid/therapeutisch gebruik
KW - microbiële gevoeligheidstest
KW - Nederland
KW - penicillaanzuur/analogen en derivaten
KW - peperacilline/therapeutisch gebruik
KW - Roemenië
KW - zilversulfadiazine/therapeutisch gebruik
KW - bètalactamase/stofwisseling
U2 - 10.1007/s10096-017-3118-1
DO - 10.1007/s10096-017-3118-1
M3 - Article
C2 - 29063446
SN - 0934-9723
VL - 37
SP - 175
EP - 183
JO - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
JF - European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
IS - 1
ER -